PROT Announces Material Agreement with the University of Miami
Complete the form below to unlock access to ALL audio articles.
Proteonomix, INC. has announced that it has entered into an agreement with the University of Miami to conduct a Clinical Study entitled "UMK 121 in Patients with Liver Disease."
Under the agreement The Company and The University have agreed to conduct a clinical study entitled "UMK 121 in Patients with Liver Disease."
The University will pay expenses associated with the clinical study and The Company shall contribute $105,000 to assist with the clinical study.
Michael Cohen, President of the Company, stated: "We would like to thank the University for their generous assistance and agreement to conduct a clinical trial of UMK-121. The Company has previously described, the terms of the agreement to license, develop and the patent application of the UMK 121 technology. The Company will work together with the University and the principal investigators to initiate the clinical study."
Mr. Cohen continued, "Our UMK-121 pharmaceutical therapy is advancing toward its first clinical trial in ESLD ('End Stage Liver Disease') patients. The Company hopes to provide information about the clinical study in the upcoming weeks and months The Company is working diligently to advance this product line into a clinical trial."
